{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:02:20Z","timestamp":1791619340951,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>A MASCC\/ISOO Clinical Practice Statement (CPS) aims to provide clinicians with a guide for managing oral conditions in cancer patients. This CPS addresses dental care prior to chemotherapy, hematopoietic cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, and other treatments for hematologic malignancies in pediatric, adult, and elderly patients. Guidance on optimal timing for resuming dental treatment post-therapy is also included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This CPS was developed through a critical evaluation of the literature, followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC\/ISOO. Information is presented in succinct bullet points and a table to create a practical manual on the best standards of care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients undergoing anti-cancer therapy require a thorough dental assessment and treatment. Pre-therapy dental care aims to prevent oral infection, systemic pathogen spread, oral pain, local irritation, and risk of aspiration and to educate patients on oral hygiene and managing the expected common oral complications. This preventive approach supports oral intake, relieves pain, prevents treatment interruptions, enhances quality of life, and potentially reduces mortality. This CPS outlines the essential considerations for the dental evaluation and treatment, focusing on key dental diagnoses, procedural prioritization, and timing relative to the hemato-oncologic therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This CPS provides clinicians with strategies for effective dental clearance, improving patient outcomes and minimizing complications during and after anti-cancer therapy. CAR T-cell therapy introduces additional considerations in the dental treatment plan before and immediately after the cytoreductive therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09845-4","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:39:17Z","timestamp":1757745557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["MASCC\/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-6529","authenticated-orcid":false,"given":"Yehuda","family":"Zadik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Raber-Durlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Majorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanessa","family":"Miranda-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Elad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"1","key":"9845_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.oraloncology.2006.12.006","volume":"44","author":"S Elad","year":"2008","unstructured":"Elad S, Thierer T, Bitan M, Shapira MY, Meyerowitz C (2008) A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncol 44(1):37\u201342. https:\/\/doi.org\/10.1016\/j.oraloncology.2006.12.006","journal-title":"Oral Oncol"},{"issue":"11","key":"9845_CR2","doi-asserted-by":"publisher","first-page":"e1397","DOI":"10.1200\/OP.20.00107","volume":"16","author":"EE Watson","year":"2020","unstructured":"Watson EE, Metcalfe JE, Kreher MR, Maxymiw WG, Glogauer M, Schimmer AD (2020) Screening for dental infections achieves 6-fold reduction in dental emergencies during induction chemotherapy for acute myeloid leukemia. JCO Oncol Pract 16(11):e1397\u2013e1405. https:\/\/doi.org\/10.1200\/OP.20.00107","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"9845_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00520-024-08991-5","volume":"32","author":"LLA van Gennip","year":"2024","unstructured":"van Gennip LLA, Thomas RZ, Bulthuis MS, Hannink G, Bronkhorst EM, Blijlevens NMA et al (2024) Oral foci of infection and their relationship with hospital stay after haematopoietic cell transplantation. Support Care Cancer 32(12):816. https:\/\/doi.org\/10.1007\/s00520-024-08991-5","journal-title":"Support Care Cancer"},{"key":"9845_CR4","unstructured":"Rankin KV, Jones DL, Redding SW, Editors (2008) Oral health in cancer therapy: a guide for health care professionals, 3rd ed. Available at: https:\/\/www.exodontia.info\/wp-content\/uploads\/2021\/07\/Oral_Health_in_Cancer_Therapy_-_A_Guide_for_Health_Care_Professionals_3rd_edition.pdf. Accessed 15 Jan 2025"},{"issue":"1","key":"9845_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/odi.13329","volume":"27","author":"FKL Spijkervet","year":"2021","unstructured":"Spijkervet FKL, Schuurhuis JM, Stokman MA, Witjes MJH, Vissink A (2021) Should oral foci of infection be removed before the onset of radiotherapy or chemotherapy? Oral Dis 27(1):7\u201313. https:\/\/doi.org\/10.1111\/odi.13329","journal-title":"Oral Dis"},{"key":"9845_CR6","first-page":"3","volume":"9","author":"National Institutes of Health Consensus Development Panel","year":"1990","unstructured":"National Institutes of Health Consensus Development Panel (1990) Consensus statement: Oral complications of cancer therapies. NCI Monogr 9:3\u20138.","journal-title":"NCI Monogr"},{"key":"9845_CR7","unstructured":"Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 49(RR-10):1\u2013125, CE1\u20137"},{"issue":"1","key":"9845_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/146532401753156403","volume":"3","author":"CDC","year":"2001","unstructured":"CDC, Infectious Disease Society of America, the American Society of Blood and Marrow Transplantation (2001) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 3(1):41\u201354. https:\/\/doi.org\/10.1080\/146532401753156403","journal-title":"Cytotherapy"},{"issue":"1","key":"9845_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00520-014-2378-x","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23(1):223\u2013236. https:\/\/doi.org\/10.1007\/s00520-014-2378-x","journal-title":"Support Care Cancer"},{"issue":"2","key":"9845_CR10","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML et al (2020) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2):e001511. https:\/\/doi.org\/10.1136\/jitc-2020-001511","journal-title":"J Immunother Cancer"},{"issue":"35","key":"9845_CR11","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39(35):3978\u20133992. https:\/\/doi.org\/10.1200\/JCO.21.01992","journal-title":"J Clin Oncol"},{"key":"9845_CR12","unstructured":"American Academy of Pediatric Dentistry (2023) Dental management of pediatric patients receiving immunosuppressive therapy and\/or head and neck radiation. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; pp. 549\u201358."},{"key":"9845_CR13","unstructured":"PDQ Supportive and Palliative Care Editorial Board (2024) Oral complications of cancer therapies (PDQ\u00ae): Health professional version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US)."},{"issue":"6","key":"9845_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.adaj.2018.01.019","volume":"149","author":"E Watson","year":"2018","unstructured":"Watson E, Wood RE, Maxymiw WG, Schimmer AD (2018) Prevalence of oral lesions in and dental needs of patients with newly diagnosed acute leukemia. J Am Dent Assoc 149(6):470\u2013480. https:\/\/doi.org\/10.1016\/j.adaj.2018.01.019","journal-title":"J Am Dent Assoc"},{"issue":"8","key":"9845_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s00520-024-08690-1","volume":"32","author":"JE Raber-Durlacher","year":"2024","unstructured":"Raber-Durlacher JE, Zadik Y, Treister NS, Stempler N, Bruno JS, Epstein JB et al (2024) MASCC\/ISOO clinical practice statement: current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation. Support Care Cancer 32(8):550. https:\/\/doi.org\/10.1007\/s00520-024-08690-1","journal-title":"Support Care Cancer"},{"issue":"6","key":"9845_CR16","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1111\/odi.14911","volume":"30","author":"Y Zadik","year":"2024","unstructured":"Zadik Y, Krasovsky A, Cohen R, Rettman A, Aframian DJ, Avni B et al (2024) Impact of dental clearance on bacteremia in hematopoietic cell transplantation. Oral Dis 30(6):4011\u20134013. https:\/\/doi.org\/10.1111\/odi.14911","journal-title":"Oral Dis"},{"issue":"12","key":"9845_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.amjmed.2010.08.009","volume":"123","author":"CH Hong","year":"2010","unstructured":"Hong CH, Allred R, Napenas JJ, Brennan MT, Baddour LM, Lockhart PB (2010) Antibiotic prophylaxis for dental procedures to prevent indwelling venous catheter-related infections. Am J Med 123(12):1128\u20131133. https:\/\/doi.org\/10.1016\/j.amjmed.2010.08.009","journal-title":"Am J Med"},{"key":"9845_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.oraloncology.2016.11.015","volume":"64","author":"AA Owosho","year":"2017","unstructured":"Owosho AA, Tsai CJ, Lee RS, Freymiller H, Kadempour A, Varthis S et al (2017) The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): the Memorial Sloan Kettering Cancer Center experience. Oral Oncol 64:44\u201351. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.11.015","journal-title":"Oral Oncol"},{"issue":"5","key":"9845_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws: 2022 update. J Oral Maxillofac Surg 80(5):920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"9845_CR20","unstructured":"PDQ Supportive and Palliative Care Editorial Board (2024) Oral complications of cancer therapies (PDQ\u00ae): patient version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US)"},{"issue":"20","key":"9845_CR21","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415.PMID:36800563","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL (2023) How I treat cytopenias after CAR T-cell therapy. Blood 141(20):2460\u20132469. https:\/\/doi.org\/10.1182\/blood.2022017415.PMID:36800563","journal-title":"Blood"},{"key":"9845_CR22","unstructured":"American Dental Association Research Services and Scientific Information (2023) Silver diamine fluoride. ADA Library & Archives. Available at: https:\/\/www.ada.org\/resources\/ada-library\/oral-health-topics\/silver-diamine-fluoride. Accessed 15 Jan 2025"},{"key":"9845_CR23","doi-asserted-by":"publisher","unstructured":"Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research (2021) Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation. 143(20):e963-e978. https:\/\/doi.org\/10.1161\/CIR.0000000000000969","DOI":"10.1161\/CIR.0000000000000969"},{"issue":"39","key":"9845_CR24","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"V Delgado","year":"2023","unstructured":"Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H (2023) 2023 ESC guidelines for the management of endocarditis. Eur Heart J 44(39):3948\u20134042. https:\/\/doi.org\/10.1093\/eurheartj\/ehad193","journal-title":"Eur Heart J"},{"issue":"8","key":"9845_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/bloodadvances.2018030387","volume":"3","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M et al (2019) Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. Blood Adv 3(8):1197\u20131210. https:\/\/doi.org\/10.1182\/bloodadvances.2018030387","journal-title":"Blood Adv"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:39:55Z","timestamp":1760672395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9845"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09845-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Y Zadik, A Majorana, W Miranda-Silva, S Yang, N Blijlevens, and S Elad reported no relevant financial or non-financial interests to disclose. JE Raber-Durlacher received in kind support from Thor Photomedicine Ltd. JE Raber-Durlacher is also Deputy Associate Editor of Supportive Care Cancer. JB Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. JB Epstein is also the Associate Editor-in-Chief for Supportive Care in Cancer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MASCC\/ISOO OCSG Statements have been developed to facilitate the expert-opinion based management of oral complications of cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. The Statement authors and the MASCC\/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"853"}}